- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03299777
Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan
Compare the Fibroscan results of preeclamptic women to normal controls and to find out if the changes are reversible after labor.
Materials and Methods
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The purpose of the study is to compare the Fibroscan results of preeclamptic women to normal controls and to find out if the changes are reversible after labor.
Materials and Methods This prospective observational case-control study will include 50 women admitted to the fetal-maternal Unit at 24 - 41 weeks gestation and diagnosed with mild/severe preeclampsia. Preeclampsia is diagnosed as a new onset of hypertension over 140/90, at least two measurements at least four hours apart, and proteinuria (≥+1 in dipstick or >300 mg/24 hr) after 20 weeks of gestation in a previously normotensive woman.
A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period. Demographic, clinical, laboratory and sonographic data for the women participating will be collected from their chart. All patients diagnosed with preeclampsia will undergo the following workup: sign and symptoms evaluation, blood pressure follow up, 24-hour protein excretion in grams per day, complete blood count, hepatic function test: AST, ALT and coagulation study, HBA1C, coagulation function test and fibrotest. The Fibroscan test will be performed by a trained hepatologist, who was blind to the women diagnosis. The fibroscan test will be done during the admission after the diagnosis of preeclampsia, after delivery and 6 weeks post-partum.
Commonly used cutoffs are >7 kPa for significant fibrosis. Statistical analysis will be performed with SPSS using Mann Whitney test. Continuous variables will be analyzed using the student's T test and categorical variables were analyzed using 2. Statistical significance was set at a P value of < 0.05. The local institutional review board approved this study.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
-
Nahariya, Israel
- Rekruttering
- Galil Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Fetal-maternal Unit at 24 - 41 weeks gestation and diagnosed with mild/severe preeclampsia
Exclusion Criteria:
- Age less then 18
- Fetal-maternal less then 24 weeks
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Control group
A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period
|
Preeclampsia group
All patients diagnosed with preeclampsia will undergo the fibroscan test.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Comparing the Fibroscan results of preeclamptic women to normal controls and to find out if the changes are reversible after labor. Fibrotic tissue differs from healthy tissue in the way it responds to excitation
Tidsramme: 2 years
|
Transient elastography is performed using transducer-induced vibrations at low frequency (50 Hz) and amplitudes.
The transmitted shear waves propagate through the liver parenchyma.
Pulse-echo ultrasound acquisition is used to follow the propagation of the shear wave and to measure its average speed.
Results are expressed in kPa and can range from 2.5 to 75 kPa.
Commonly used cutoffs in clinical settings are >7 kPa for significant fibrosis and >11 to 14 kPa for cirrhosis and CAP>270 db/m2 for significant steatosis.
|
2 years
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Maya Wolf, MD, Western Galilee Medical Center
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 0036-17-NHR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Preeklampsi
-
Penn State UniversityRekruttering
-
Fenway Community HealthHarvard UniversityFullførtPre-eksponeringsprofylakseForente stater
-
Thomas Jefferson UniversityFullførtPre-oksygenering
-
University of FloridaNational Institutes of Health (NIH); National Institute on Aging (NIA)FullførtPre-klinisk deaktivertForente stater
-
University of Illinois at ChicagoNational Institute of Nursing Research (NINR)RekrutteringSexarbeid | Pre-eksponeringsprofylakseForente stater
-
Chang Gung UniversityRekruttering
-
Erasme University HospitalFullførtPre-anestetisk konsultasjonBelgia
-
Singapore General HospitalSengkang General Hospital; Duke-NUS Graduate Medical SchoolFullførtFalle | Fallforebygging | Pre- skrøpeligSingapore
-
Fundación para la Investigación del Hospital Clínico...Fullført
-
University of WashingtonFullførtPre-induksjon Cervikal modning